Nanomedicine Approaches for Corneal Diseases
Source abstract
Abstract
Corneal diseases are the third leading cause of blindness globally. Topical nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, antibiotics and tissue transplantation are currently used to treat corneal pathological conditions. However, barrier properties of the ocular surface necessitate high concentration of the drugs applied in the eye repeatedly. This often results in poor efficacy and several side-effects. Nanoparticle-based molecular medicine seeks to overcome these limitations by enhancing the permeability and pharmacological properties of the drugs. The promise of nanomedicine approaches for treating corneal defects and restoring vision without side effects in preclinical animal studies has been demonstrated. Numerous polymeric, metallic and hybrid nanoparticles capable of transporting genes into desired corneal cells to intercept pathologic pathways and processes leading to blindness have been identified. This review provides an overview of corneal diseases, nanovector properties and their applications in drug-delivery and corneal disease management.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Corneal Surgery and Treatments · Advanced Drug Delivery Systems · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Ophthalmology Veterinary Medicine & Surgery, Columbia, MO 65211, USA
Singapore Eye Research Institute, 20 College Road, 169856, Singapore
Harry S. Truman Memorial Veteran Hospital, Columbia, MO 65201, USA
Mason Eye Institute, University of Missouri-Columbia, Columbia, MO 65211, USA
References (100+)
Show source-provided references
1. The cornea—Structure and macromolecules in health and disease. A review
2. Confocal microscopy of the cornea10.1016/S1350-9462(98)00028-7 ↗
3. The cellular basis of corneal transparency: Evidence for ‘corneal crystallins’10.1242/jcs.112.5.613 ↗
4. Characteristics of the human ocular surface epithelium10.1016/S1350-9462(01)00007-6 ↗
5. The corneal endothelium10.1038/eye.1990.53 ↗
6. Corneal Stroma Microfibrils10.1016/j.exer.2015.01.014 ↗
7. Fibrosis in the anterior segments of the eye10.2174/1871530311006040331 ↗
8. The molecular basis of corneal transparency10.1016/j.exer.2010.06.021 ↗
9. The eye in systemic inflammatory diseases10.1016/S0140-6736(04)17554-5 ↗
10. Oxidative stress in diseases of the human cornea10.1016/j.freeradbiomed.2008.07.021 ↗
11. Apoptosis in the initiation, modulation and termination of the corneal wound healing response10.1016/j.exer.2007.06.009 ↗
12. Corneal scar formation10.1016/0014-4835(73)90176-0 ↗
13. Role of transforming growth factor Beta in corneal function, biology and pathology
14. Dynamics of the expression of intermediate filaments vimentin and desmin during myofibroblast differentiation after corneal injury10.1016/S0014-4835(09)00247-4 ↗
15. Reducing peak corneal haze after photorefractive keratectomy in rabbits: Prednisolone acetate 1.00% versus cyclosporine A 0.05%10.1016/j.jcrs.2010.11.035 ↗
16. Corticosteroids for bacterial keratitis: The steroids for corneal ulcers trial (SCUT)10.1001/archophthalmol.2011.315 ↗
17. Laser epithelial keratomileusis with mitomycin C: indications and limits10.3928/1081-597X-20040903-13 ↗
18. Serious corneoscleral complications after pterygium excision with mitomycin C10.1136/bjo.86.3.357 ↗
19. The emerging nanomedicine landscape10.1038/nbt1006-1211 ↗
20. Nanotechnology for molecular imaging and targeted therapy10.1161/01.CIR.0000059651.17045.77 ↗
21. Nanomedicine10.1056/NEJMra0912273 ↗
22. Applications of nanoparticles in ophthalmology10.1016/j.preteyeres.2010.08.002 ↗
23. Nanotechnology for ocular therapeutics and tissue repair10.1586/17469899.3.4.431 ↗
24. Regenerative nanomedicine in vision restoration10.1016/j.mayocp.2013.05.025 ↗
25. Polyethylenimine-conjugated gold nanoparticles: Gene transfer potential and low toxicity in the cornea10.1016/j.nano.2011.01.006 ↗
26. Attenuation of corneal myofibroblast development through nanoparticle-mediated soluble transforming growth factor-β type II receptor (sTGFβRII) gene transfer
27. Pirfenidone nanoparticles improve corneal wound healing and prevent scarring following alkali burn10.1371/journal.pone.0070528 ↗
28. BMP7 gene transfer via gold nanoparticles into stroma inhibits corneal fibrosis in vivo10.1371/journal.pone.0066434 ↗
29. Life at front: Dissecting bacterial-host interactions at the ocular surface10.1016/S1542-0124(12)70612-2 ↗
30. Distribution of mucins at the ocular surface10.1016/S0014-4835(03)00204-5 ↗
31. Role of lactoferrin in the tear film10.1016/j.biochi.2008.07.007 ↗
32. Antimicrobial defensin peptides of the human ocular surface10.1136/bjo.83.6.737 ↗
33. Ocular surface expression and in vitro activity of antimicrobial peptides10.1080/02713680701446653 ↗
34. Microbial keratitis10.1136/bjo.87.7.805 ↗
35. Risk factors and causative organisms in microbial keratitis10.1097/ICO.0b013e318156caf2 ↗
36. Bacterial keratitis: predisposing factors, clinical, and microbiological review of 300 cases10.1136/bjo.87.7.834 ↗
37. Predisposing factors and etiologic diagnosis of ulcerative keratitis10.1097/ICO.0b013e31815ca0bb ↗
38. Ophthalmic drug delivery systems-recent advances10.1016/S1350-9462(97)00002-5 ↗
39. Ocular toxicity of fluoroquinolones10.1111/j.1442-9071.2007.01552.x ↗
40. Sliding of the epithelium in experimental corneal wounds
41. Stromal-Epithelial interactions in the cornea10.1016/S1350-9462(98)00017-2 ↗
42. Corneal wound healing after ultraviolet-A/riboflavin collagen cross-linking: A rabbit study10.3928/1081597X-20101201-02 ↗
43. Corneal wound healing10.1097/00055735-200408000-00006 ↗
44. Corneal keratocytes: in situ and in vitro organization of cytoskeletal contractile proteins
45. Keratocyte and fibroblast phenotypes in the repairing cornea10.1016/S1350-9462(98)00033-0 ↗
46. Extracellular matrix and wound healing10.1097/00055735-200108000-00001 ↗
47. Hevin plays a pivotal role in corneal wound healing10.1371/journal.pone.0081544 ↗
48. PEDF: A pigment epithelium-derived factor with potent neuronal differentiative activity10.1016/0014-4835(91)90248-D ↗
49. PEDF-derived peptide inhibits corneal angiogenesis by suppressing VEGF expression10.1016/j.mvr.2012.02.006 ↗
50. Corneal avascularity is due to soluble VEGF receptor-110.1038/nature05249 ↗
51. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis10.1167/iovs.03-0940 ↗
52. Molecular cloning of a new angiopoietinlike factor from the human cornea
53. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression10.1038/35107085 ↗
54. New thoughts on the immunology of corneal transplantation10.1038/sj.eye.6700615 ↗
55. Immune privilege and angiogenic privilege of the cornea10.1159/000099253 ↗
56. Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis)
57. Differential expression of pro- and antiangiogenic factors in mouse strain- dependent hypoxia-induced retinal neovascularization10.1038/labinvest.3700277 ↗
58. Induction of macrophage inflammatory protein-1alpha and vascular endothelial growth factor during inflammatory neovascularization in the mouse cornea10.1023/A:1026554404941 ↗
59. Activated macrophages induce neovascularization through upregulation of MMP-9 and VEGF in rat corneas10.1097/ICO.0b013e31823f8b40 ↗
60. Corneal neovascularization10.1097/00055735-200108000-00002 ↗
61. Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model10.1016/j.exer.2014.06.006 ↗
62. Corneal neovascularization: molecular events and therapeutic options10.2174/187221309789257450 ↗
63. Nanoparticle applications in ocular gene therapy10.1016/j.visres.2007.07.012 ↗
64. The forthcoming applications of gold nanoparticles in drug and gene delivery systems10.1016/j.jconrel.2009.12.006 ↗
65. Efficient gene delivery vectors by tuning the surface charge density of amino acid-functionalized gold nanoparticles10.1021/nn800507t ↗
66. The effect of conjugation to gold nanoparticles on the ability of low molecular weight chitosan to transfer DNA vaccine10.1016/j.biomaterials.2007.09.007 ↗
67. Effects of a potent antioxidant, platinum nanoparticle, on the lifespan of Caenorhabditis elegans10.1016/j.mad.2008.02.011 ↗
68. Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: Characterization, in vitro and in vivo study10.1248/cpb.59.272 ↗
69. Microscopic and spectroscopic evaluation of novel PLGA-chitosan Nanoplexes as an ocular delivery system10.1016/j.colsurfb.2010.09.010 ↗
70. Bioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue10.1038/gt.2008.16 ↗
71. Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells
72. The use of mucoadhesive polymers in ocular drug delivery10.1016/j.addr.2005.07.005 ↗
73. A new tool for the transfection of corneal endothelial cells: calcium phosphate nanoparticles10.1016/j.actbio.2011.09.013 ↗
74. Nano neuro knitting: Peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision10.1073/pnas.0600559103 ↗
75. Impediments to eye transplantation: ocular viability following optic-nerve transection or enucleation10.1136/bjo.2008.155267 ↗
76. Cell delivery in regenerative medicine: the cell sheet engineering approach10.1016/j.jconrel.2006.06.022 ↗
77. The graft of autologous adipose-derived stem cells in the corneal stromal after mechanic damage10.1371/journal.pone.0076103 ↗
78. Dendrimer crosslinked collagen as a corneal tissue engineering scaffold: Mechanical properties and corneal epithelial cell interactions10.1016/j.biomaterials.2006.04.022 ↗
79. Nanocarriers as an emerging platform for cancer therapy10.1038/nnano.2007.387 ↗
80. Dendrimers as drugs: Discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention10.1021/mp050023q ↗
81. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles10.1038/nature08956 ↗
82. Quantum dots versus organic dyes as fluorescent labels10.1038/nmeth.1248 ↗
83. Biological applications of gold nanoparticles10.1039/b712170a ↗
84. Multiplexed multicolor Raman imaging of live cells with isotopically modified single walled carbon nanotubes10.1021/ja806242t ↗
85. Preparation and evaluation of a contact lens vehicle for puerarin delivery10.1163/156856209X415774 ↗
86. Extended cyclosporine delivery by silicone-hydrogel contact lenses10.1016/j.jconrel.2011.06.028 ↗
87. Sustained ocular delivery of ciprofloxacin using nanospheres and conventional contact lens materials10.1167/iovs.11-8215 ↗
88. Ocular release of timolol from molecularly imprinted soft contact lenses10.1016/j.biomaterials.2004.04.030 ↗
89. Imprinted soft contact lenses as norfloxacin delivery systems10.1016/j.jconrel.2006.05.003 ↗
90. In vitro controlled release of an anti-inflammatory from daily disposable therapeutic contact lenses under physiological ocular tear flow10.1016/j.ejpb.2012.01.015 ↗
91. Nanoscale engineering of biomimetic surfaces: Cues from the extracellular matrix10.1007/s00441-009-0896-5 ↗
92. Nanosponges—A completely new nano-horizon: Pharmaceutical applications and recent advances10.3109/03639045.2012.694610 ↗
93. Nanosponges encapsulating dexamethasone for ocular delivery: Formulation design, physicochemical characterization, safety and corneal permeability assessment10.1166/jbn.2013.1594 ↗
94. Saito, R., Dresselhaus, G., and Dresselhaus, M.S. (1998). Physical Properties of Carbon Nanotubes, Imperial College Press.10.1142/9781860943799 ↗
95. Applications of carbon nanotubes10.1007/3-540-39947-X_14 ↗
96. Carbon nanotubes for delivery of small molecule drugs10.1016/j.addr.2013.08.005 ↗
97. Topical delivery of ocular therapeutics: Carrier systems and physical methods10.1111/jphp.12132 ↗
98. Dispersion of microemulsion drops in HEMA hydrogel: A potential ophthalmic drug delivery vehicle10.1016/j.ijpharm.2004.11.033 ↗
99. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future10.1016/S0169-409X(00)00118-6 ↗
100. The impact of nanobiotechnology on the development of new drug delivery systems10.2174/1389201053167158 ↗